A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • Biopsy-proven Kaposi's sarcoma (KS) with multiple cutaneous lesions.
• • Minimum life expectancy of 3 months.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Clinically significant cardiac disease.
• • Known hemorrhagic diathesis or active bleeding disorder.
• • Clinically apparent vascular disease.
• • Known lipoprotein disorders.
• • History of seizure disorder or central nervous system (CNS) metastasis.
• • Additional malignancy.
• Concurrent Medication:
• Excluded:
• • Cardiac agents.
• • Anticoagulants.
• • Thrombolytic agents.
• • Nonsteroidal anti-inflammatory drugs.
• • Corticosteroids.
• • Aspirin.
• • Vasodilators.
• Patients with the following are excluded:
• • Additional malignancies or other conditions listed in Patient Exclusion Co-Existing Conditions.
• Prior Treatment:
• Excluded within 4 weeks of study entry:
• • Chemotherapy.
• • Radiotherapy.
• • Immunotherapy.